FeedbackDrug-susceptible TB treatment
Participants in the Guideline Development group meeting on Drug-susceptible TB in 2009
Guideline Development Group
Solange Cavalcante, TB Control Program Coordinator, Rio de Janeiro municipality, Rio de Janeiro, RJ, Brazil
Jeremiah Muhwa Chakaya (Chairperson), Technical Expert, National Leprosy and TB Programme, Kenya Medical Research Institute, Nairobi, Kenya
Saidi M. Egwaga, Programme Manager, National TB and Leprosy Programme, Ministry of Health and Social Welfare, Dar es Salaam, United Republic of Tanzania
Robert Gie, Professor of Medicine, Department of Paediatrics & Child Health, University of Stellenbosch, Faculty of Medicine, Tygerberg, South Africa
Peter Gondrie, Executive Director, KNCV Tuberculosis Foundation, The Hague, Netherlands
Anthony D. Harries, Senior Consultant, International Union Against Tuberculosis and Lung Disease, Winchester, Hants, England
Phillip Hopewell, Professor of Medicine, Division of Pulmonary & Critical Care, San Francisco General Hospital, University of California San Francisco (UCSF), San Francisco, USA
Blessina Kumar, Global Coalition of TB advocates, New Delhi, India
Kitty Lambregts-van Weezenbeck, Senior Consultant, KNCV Tuberculosis Foundation, The Hague, Netherlands
Sundari Mase, Division of TB Elimination National Centre for HIV, STD and TB, Centers for Disease Control and Prevention, Atlanta, USA
Richard Menzies, Director, Respiratory Division, MUHC and McGill University, Montreal, Canada
Anna Nakanwagi Mukwaya, Chief of Party, TBCAP Program, International Union Against Tuberculosis and Lung Disease, Wandegeya, Uganda
Mahshid Nasehi, National TB Programme Manager, Centre for Disease Control & Prevention, Ministry of Health and Medical Education, Tehran, Islamic Republic of Iran
Andrew Nunn, Professor of Epidemiology, Associate Director, MRC Clinical Trials Unit, London, England
Madhukar Pai, Assistant Professor, Department of Epidemiology, Biostatistics & Occupational Health, McGill University, Montreal, Canada
Holger Schünemann, Methodologist, Chair, McMaster University Medical Centre, Clinical Epidemiology and Biostatistics, Health Sciences Centre Hamilton, Canada
Zarir F. Udwadia, Private Practitioner and Consultant Physician, Hinduja Hospital and Research Centre, Mumbai, India
Andrew Vernon, Division of TB Elimination, National Centre for HIV, STD and TB, Centers for Disease Control and Prevention, Atlanta, USA
Rozalind G. Vianzon, National TB Programme Manager, National Center for Disease Control and Prevention, Department of Health, Manila, Philippines
Virginia Williams, TB Project Director, International Council of Nurses, Suffolk, England
External Review Group
Olayide Akanni, Nigeria
Margareth Pretti Dalcolmo, Brazil
Francis Drobniewski, United Kingdom
Paula Fujiwara, USA
Salmaan Keshavjee, USA
G.R. Khatri, India
Michail Perelman, Russian Federation
Charles Sandy, Zimbabwe
Pedro Guillermo Suarez, Peru
Marieke van der Werf, Netherlands
Wang Lixia, China
Nadia Wiweko, Indonesia
Mohamed Abdel Aziz, The Global Fund to Fight AIDS, Tuberculosis and Malaria
Daniel Kibuga, WHO Regional Office for Africa
Giampaolo Mezzabotta, WHO Viet Nam
Jamhoih Tonsing, Family Health International Cambodia
Richard Zaleskis, WHO Regional Office for Europe
Participants in the Guideline Development Group meeting in 2016
Guideline Development Group
Si Thu Aung, Deputy Director (TB) and National TB Programme Manager, Department of Public Health, Ministry of Health Nay Pyi Taw, Myanmar (unable to attend the meeting)
Frank Bonsu, National TB Programme Manager Ministry of Health, Accra, Ghana
Jeremiah Muhwa Chakaya, clinician, National TB Programme Manager Kemri, Nairobi, Kenya
Lucy Chesire, Nairobi, Kenya
Daniela Cirillo, Head of Emerging Bacterial Pathogens Unit, WHO Collaborating Centre and TB Supranational Reference Laboratory, San Raffaele Scientific Institute Milano, Italy
Poonam Dhavan, Migration Health Programme Coordinator, International Organization for Migration Geneva, Switzerland (unable to attend the meeting)
Kelly Dooley, Associate Professor of Medicine, Pharmacology & Molecular Sciences Divisions of Clinical Pharmacology & Infectious Diseases, Center for Tuberculosis Research Faculty Leader, Janeway Firm of the Osler Residency Program, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America
Kathy Fiekert, Senior TB Consultant, KNCV Tuberculosis Foundation The Hague, Netherlands
Paula Fujiwara, Scientific Director International Union Against Tuberculosis and Lung Disease (The Union), Paris, France
Mike Frick, TB/HIV Project Treatment Action Group New York, NY, United States of America
Andrei Mariandyshev, Head of Phthisiopulmonary Department Arkhangelsk, Russian Federation
Nguyen Viet Nhung, Director of National Lung Hospital Manager of Vietnam of National TB Programme, Hanoi, Viet Nam
Ejaz Qadeer, Ministry of Health, Islamabad, Pakistan
Abdul Hamid Salim, Advisor to the National TB Programme Bangladesh on Global Fund and MDR-TB TB Gate, Leprosy Hospital Compound, Mohakhali Dhaka, Bangladesh
Simon Schaaf, Pediatrician, Pediatrics and Child Health Faculty of Medicine and Health Sciences, University of Stellenbosch South Africa
Holger Schünemann (Chair), Methodologist, McMaster University, Canada
Pedro Guillermo Suarez, Management Sciences for Health Arlington, VA, United States of America (unable to attend the meeting)
Carrie Tudor, TB Project Director International Council of Nurses Durban, South Africa
Justin Wong Yun Yaw, Head, Disease Control Division Ministry of Health, Jalan Menteri Besar Brunei
External Review Group
Mohammed Aziz, WHO Eastern Mediterranean Regional Office WHO
Masoud Dara, WHO Europe Regional Office WHO
Riitta Dlodlo, International Union Against Tuberculosis and Lung Disease, France
Celine Garfin, Ministry of Health Philippines National programme
Mirtha del Granado, WHO Americas Regional Office WHO
Khurshid Alam Hyder, WHO South-East Asia Regional Office WHO
Vaira Leimane, Riga East University Hospital Centre of Tuberculosis and Lung Diseases Latvia
Nobuyuki Nishikiori, WHO Western Pacific Regional Office WHO
Lee Reichman, Rutgers New Jersey Medical School The United States
Rohit Sarin, National Institute of TB & Respiratory Diseases Ministry of Health, India
Dalene von Delft, TB Proof South Africa
Fraser Wares, Royal Dutch Tuberculosis Foundation (KNCV) The Netherlands
Evidence reviewers
Narges Alipanah, Santa Clara Valley Medical Center San Jose, United States of America
Lelia Chaisson, Department of Epidemiology Johns Hopkins Bloomberg School of Public Health, United States of America
James Johnston, TB Services British Columbia Centre for Disease Control, Canada
Jennifer Ho, Woolcock Institute of Medical Research, University of Sydney Australia
Dick Menzies, RECRU/ Montreal Chest Institute Montreal, Quebec, Canada
Payam Nahid, University of California, San Francisco, United States of America
Observers and external partners
Amy Bloom, Senior Technical Advisor, Bureau of Global Health
US Agency for International Development (USAID)
Janet Ginnard, UNITAID, Geneva, Switzerland
Participants in the Guideline Development Group meeting in 2021
Guideline Development Group
Charles Daley (Co-Chair), National Jewish Health, Denver (clinician), United States of America
Tamara Kredo (Co-Chair), South Africa Medical Research Council (methodologist, academia), South Africa
Susan Abdel Rahman, Children’s Mercy Kansas City (clinician), United States of America
Kunle Victor Babawale, Government of Nigeria (National TB programme, end user), Nigeria
Grania Brigden, The International Union Against TB and Lung Disease (clinician, technical NGO), France
Xu Caihong, Government of China (National TB programme, end user), People’s Republic of China
Daniela Cirillo, TB Supranational Reference Laboratory Milan (TB diagnostics specialist), Italy
Gerry Davies, The University of Liverpool (clinician, academia), United Kingdom
Fernanda Dockhorn Costa Johansen, Government of Brazil (National TB programme, end user), Brazil
Allan Fabella, Government of the Philippines (National TB programme, end user), The Philippines
Anneke Hesseling, Stellenbosch University (clinician, academia), South Africa
Cathy Hewison, Médecins sans Frontières (clinician, technical NGO), France
Muhammad Amir Khan, Association for Social Development (civil society representative), Pakistan
Khum Kim Eam, Government of Cambodia (National TB programme, end user), Cambodia
Ravinder Kumar, Government of India (National TB programme, end user), India
Endang Lukitosari, Government of Indonesia (National TB programme, end user), Indonesia
Aung Kya Jai Maug, The Damien Foundation (clinician, technical NGO), Bangladesh
Graeme Meintjes, The University of Cape Town (clinician, academia), South Africa
Jeremiah Chakaya Muhwa, The Respiratory Society of Kenya (clinician, professional association), Kenya
Andrew Owuor, Government of Kenya (National TB programme, end user), Kenya
Laia Ruiz Mingote, Independent consultant (civil society representative), Spain
Anastasia Samoilova, Government of the Russian Federation (National TB programme, end user), Russian Federation
Hadi Syed Hussain, Government of Pakistan (National TB programme, end user), Pakistan
Carrie Tudor, International Council of Nurses (nurse, technical NGO), South Africa
Fraser Wares, KNCV Tuberculosis Foundation (public health specialist, technical NGO), United Kingdom
External Review Group
Rafael Laniado Laborin, National TB Programme / Regional Green Light Committee, Mexico
Andrei Maryandyshev, Northern State Medical University Arkhangelsk, Russian Federation
Greg Fox, The University of Sydney, Australia
Harald Hoffmann, Supranational Reference Laboratory (Institute of Microbiology and Laboratory Medicine), Germany
Moorine Sekadde, National TB and Leprosy Programme, Uganda
Lisa Chen, Curry International Tuberculosis Center, United States of America
Ken Castro, Emory University, United States of America
Sangeeta Sharma, National Institute of Tuberculosis and Respiratory Diseases, India
Mahshid Nasehi, National TB and Leprosy Control Programmes, Iran
Giovanni Battista Migliori, Maugeri Institute, Italy
Evidence contributors and reviewers
Wendy Carr, Centers for Disease Control and Prevention, United States of America
Susan Dorman, Medical University of South Carolina, United States of America
Nora Engel, University of Maastricht, The Netherlands
Katya Kurbatova, Centers for Disease Control and Prevention, United States of America
Muthoni Mwaura, University of Maastricht, Kenya
Payam Nahid, University of California, San Francisco, United States of America
Patrick Phillips, University of California, San Francisco, United States of America
Andrew Vernon, Centers for Disease Control and Prevention, United States of America
Observers and external partners
Draurio Barreira, UNITAID, Switzerland
Padmapriyadarsini Chandrasekaran, Indian Council of Medical Research, India
Mike Frick, Treatment Action Group, United States of America
Brian Kaiser, Stop TB Partnership, Global Drug Facility, Switzerland
Ya Diul Mukadi, United States Agency for International Development, United States of America
Samuel Schumacher, FIND, Switzerland
Jamie Tonsing, Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland
Brenda Waning, Stop TB Partnership, Global Drug Facility, Switzerland
WHO Steering Group
The following staff served as the WHO Steering Committee for the development of the current policy guideline: Fuad Mirzayev (lead), Dennis Falzon, Medea Gegia, Kerri Viney, Matteo Zignol, Linh Nguyen, Annemieke Brands, Farai Mavhunga, Nazir Ismail (Global Tuberculosis Programme, WHO Headquarters), Lorenzo Moja (Essential Medicines), Vineet Bhatia (South-East Asia Regional Office), Askar Yedilbayev (European Regional Office).
Funding
USAID is acknowledged for the financial support to the guideline development process.
Drug-resistant TB treatment
WHO guidelines for the programmatic management of drug-resistant tuberculosis, 2011 update
Refer to Annex 1: GRADE evidence summary tables in the WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment. Online annexes. 9789240007062-eng.pdf (who.int), accessed 10 October 2022).
WHO treatment guidelines for isoniazid-resistant tuberculosis, 2018 update
Refer to Annex 1: GRADE evidence summary tables in the WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment. Online annexes. (9789240007062-eng.pdf, accessed 10 October 2022).
WHO treatment guidelines for rifampicin- and multidrug-resistant tuberculosis, 2018 update
Refer to Annex 1: GRADE evidence summary tables in the WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment. Online annexes. (9789240007062-eng.pdf, accessed 10 October 2022).
WHO treatment guidelines for drug-resistant TB treatment, 2020 update
Refer to Annex 1: A2 Expert panels in the WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment. Online annexes. (9789240007062-eng.pdf, accessed 13 September 2022).
WHO treatment guidelines for drug-resistant TB treatment, 2022 update
Guideline Development Group
The chairs of the GDG were Holger J. Schünemann (Chair, Grading of Recommendations Assessment, Development and Evaluation [GRADE] methodologist: Cochrane Canada & McMaster University, Canada) and Jeremiah Muhwa Chakaya (Technical expert, National TB Programme, Kenya).
The following experts served as members of the GDG: Denise Arakaki (national TB programme, enduser, clinician: Ministry of Health MDR-TB referral centre, Brazil); Padmapriyadarsini Chandrasekaran (researcher, end user: National Institute for Research in Tuberculosis, India); Daniela Maria Cirillo (laboratory specialist: San Raffaele Scientific Institute, Supranational TB Reference Laboratory, Italy); Charles Daley (pulmonologist, MDR-TB expert: National Jewish Health Hospital, United States of America); Gerry Davies (trials expert, pharmacologist: University of Liverpool, United Kingdom); Amita Gupta (scientist, maternal health medicine: Johns Hopkins University, United States of America); Elmira Gurbanova (rGLC member, clinician, end-user: Lung Clinic, University of Tartu, Estonia); Anneke Hesseling (paediatrician, end-user: Stellenbosch University, South Africa); Christoph Lange (researcher: Research Center Borstel, Germany); Christian Lienhardt (researcher, end user: French Institute for Research on Sustainable Development, France); Leslie Christine Magsayo-Salon (national TB programme, clinician (TB/HIV), end user: National TB Programme, Northern Mindanao Medical Center, The Philippines); Guy Marks (clinician, researcher: International Union Against Tuberculosis and Lung Disease); Graeme Meintjes (researcher, end user: University of Capetown, South Africa); Asif Mujtaba (clinician, end-user: Asgar Ali Hospital, Bangladesh); Mahshid Nasehi (national TB programme, end user: National Tuberculosis Programme of Iran, Islamic Republic of Iran); Nguyen Viet Nhung (national TB programme, end-user: National TB Control Programme, Ministry of Health, Viet Nam); Andrew Nunn (researcher, end user: University College London, United Kingdom); Ingrid Schoeman (former MDR-TB patient: TB PROOF, South Africa); Sabira Tahseen (laboratory, national TB programme, end-user: National TB Control Programme, Pakistan); Ye Tun (clinician, end-user: Thingankyun General Hospital, University of Medicine, Myanmar); Debrah Vambe (national TB programme, end-user: National TB Control Program, Eswatini); Andrew Vernon (trials expert, technical agency, end-user: US Centers for Disease Control and Prevention, United Sates of America); Paran Winarni (civil society representative: TB Civil Society Task Force, Indonesia Youth Movement Against TB, Indonesia); Yanlin Zhao (national TB programme, end-user: National Tuberculosis Control and Prevention Center, Chinese Center for Disease Control, China).
External Review Group
Giovanni Battista Migliori (WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Tradate, Italy); Anuj K. Bhatnagar (clinician; researcher: Rajan Babu Institute for Pulmonary Medicine and Tuberculosis, India); Lisa Chen (clinician, academic: UCSF Curry International Tuberculosis Center, United States of America); Edwin H. Herrera-Flores (clinician, end-user: Hospital Nacional MDR-TB Referral Centre, Arzobispo Loayza, Peru); Ivan Solovic (national TB programme, clinician, end-user: National Institute for TB, Lung Diseases and Thoracic Surgery, Slovakia); Rafael Laniado (clinician, end-user: National TB Programme, Mexico); Anna Cristina C. Carvalho (clinician, researcher: Fiocruz Institute, Brazil); Philipp du Cros (clinician, researcher: Burnet Institute, Australia).
Evidence reviewers
Greg Fox, Tasnim Hasan, Timothy Schlubb, Hannah Morgan and Ellie Medcalf from The University of Sydney; Claudia Denkinger and Ioana Olaru from Heidelberg University
Observers and external partners
Draurio Barreira Cravo Neto (technical manager, TB: Unitaid, Switzerland); Michael Campbell (Senior director, Tuberculosis: Clinton Health Access Initiative, Inc.); Abdul Ghafoor (Advisor MDR-TB: Ministry of National Health Services Regulations & Coordination, Pakistan); Mustapha Gidado (executive director: KNCV TB Foundation, Netherlands); Brian Kaiser (technical officer: Stop TB Partnership’s Global Drug Facility, Switzerland); YaDiul Mukadi (technical advisor: United States Agency for International Development [USAID], USA); Payam Nahid (Director: UCSF center for Tuberculosis, University of California San Francisco); Fraser Wares (Senior consultant: KNCV TB Foundation); Wojtek Wiercioch (GRADE methodologist: McMaster University, Canada); and Mohammed Yassin (senior disease advisor, TB: The Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland).
WHO Steering Group
Fuad Mirzayev (lead), Dennis Falzon, Medea Gegia, Annabel Baddeley, Nazir Ismail, Linh Nguyen, Samuel Schumacher, Sabine Verkuijl, Kerri Viney, Matteo Zignol from the WHO Global Tuberculosis Programme; Askar Yedilbayev from WHO European regional office; Corinne Simone Collette Merle from the WHO Special Programme for Research and Training in Tropical Diseases; Lorenzo Moja from the WHO Medicines Selection, Intellectual Property and Affordability / Essential Medicines; Andreas Alois Reis from WHO Health Ethics and Governance; and Olufunmilayo Lesi and Marco Vittoria from the WHO Global HIV, Hepatitis and STIs Programmes.
WHO treatment guidelines for drug-resistant TB treatment, 2025 update
Guideline Development Group
Jeremiah Muhwa Chakaya (Technical expert, National TB Programme, Kenya, London School of Hygiene and Tropical Medicine, United Kingdom) chaired the GDG. Professor Holger J. Schünemann (Professor of Public Health and Preventive Medicine at Humanitas University, Milan, Italy) and Wojtek Wiercioch (GRADE methodologist: McMaster University, Canada) served as the methodologists for developing this guideline update.
The following experts served as members of the GDG: Ashna Ashesh (WHO Civil Society Task Force – TB; Survivors Against TB, India), Erlina Burhan (Persahabatan Hospital Jakarta; Faculty of Medicine, Universitas, Indonesia), Raymond Byaruhanga (National TB and Leprosy Programme, Ministry of Health, Uganda), Daniela Cirillo (San Raffaele Supranational TB Reference Laboratory, Italy), Charles Daley (National Jewish Health Hospital, United States), Geraint Rhys Davies (University of Liverpool, United Kingdom), Fernanda Dockhorn Costa Johansen (National TB programme, Ministry of Health, Brazil); Elmira Gurbanova (Lung Clinic, University of Tartu, Estonia); Anneke Hesseling (Stellenbosch University, South Africa); Christoph Lange (Research Center Borstel, Germany); Graeme Mentjes (University of Cape Town, South Africa); Gopalan Narendran (Indian Council of Medical Research, National Institute for Research in Tuberculosis, India); Mahshid Nasehi (National Tuberculosis Programme of Iran); Kim Cuong Nguyen (National Lung Hospital, Viet Nam); Wenhong Zhang (National Medical Center for Infectious Diseases, China).
External Review Group
Philipp du Cros (clinician, researcher: Burnet Institute, Australia); Giovanni Battista Migliori (WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Tradate, Italy); Anuj K. Bhatnagar (clinician; researcher: Rajan Babu Institute for Pulmonary Medicine and Tuberculosis, India); Tasnim Hassan (University of Sydney, Australia); Lisa Chen (clinician, academic: UCSF Curry International Tuberculosis Center, United States of America); Mamel Quelapio (Tropical Disease Foundation, Philippines); Faisal Sobia (NTP team, Pakistan); Patrick Lungu (East, Central and Southern Africa Health Community, Zambia); Andrew Nunn (MRC Clinical Trials Unit at UCL, United Kingdom); Rafael Laniado (National TB Programme, Mexico); Ingrid Shoeman (former TB patient, TB Proof, South Africa).
Evidence contributors
Francesca Conradie (University of Witwatersrand), Maelenn Gouillou (MSF France), Lorenzo Guglielmetti (MSF France), Nathalie Lachenal (MSF Switzerland), Carole Mitnick (Partners in Health), Patrick Phillips (University of California, San Francisco), Francis Varaine (MSF France).
Observers and external partners
Michael Campbell (Clinton Health Access Initiative, Inc.); Maria Regina Christian (WHO country office, Indonesia); Razia Fatima (National TB programme, Pakistan); Agnes Gebhard (KNCV TB Foundation); Brian Kaiser (Global Drug Facility, Stop TB Partnership); Kobto Ghislain Koura (Tuberculosis Department, The Union); Parmar Malik (WHO country office, India); Anna Scardigli (The Global Fund), Cherise Scott (Unitaid); Brenda Waning (Global Drug Facility, Stop TB Partnership).
WHO Steering Group
Fuad Mirzayev (lead), Dennis Falzon, Medea Gegia, Annabel Baddeley, Linh Nguyen, Samuel Schumacher, Kerri Viney, Sabine Verkuijl, Matteo Zignol from the WHO Global Tuberculosis Programme; Askar Yedilbayev from WHO European regional office; and Elena Vovc from the WHO Global HIV, Hepatitis and STIs Programmes.
Tuberculosis care and support
Guidelines on tuberculosis care and support update, 2017
Guideline Development Group
Si Thu Aung, Deputy Director (TB) and National TB Programme Manager, Ministry of Health, Nay Pyi Taw, Myanmar (Unable to attend the meeting); Frank Bonsu, National TB Programme Manager, Ministry of Health, Accra, Ghana; Jeremiah Muhwa Chakaya, Clinician, National TB Programme Manager, Nairobi, Kenya; Lucy Chesire, Nairobi, Kenya; Daniela Cirillo, Head of Emerging Bacterial Pathogens Unit, WHO Collaborating Centre and TB Supranational Reference Laboratory, San Raffaele Scientific Institute, Milan, Italy; Poonam Dhavan, Migration Health Programme Coordinator, International Organization for Migration, Geneva, Switzerland (Unable to attend the meeting); Kelly Dooley, Associate Professor of Medicine, Pharmacology & Molecular Sciences, Divisions of Clinical Pharmacology & Infectious Diseases, Center for Tuberculosis Research, Faculty Leader, Janeway Firm of the Osler Residency Program, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America; Kathy Fiekert, Senior TB Consultant, Royal Dutch Tuberculosis Foundation (KNCV), The Hague, Netherlands; Paula Fujiwara, Scientific Director, International Union Against Tuberculosis and Lung Disease, Paris, France; Mike Frick, TB/HIV Project, Treatment Action Group, New York, NY, United States of America; Andrei Mariandyshev, Head of Phthisiopulmonary Department, Arkhangelsk, Russian Federation; Nguyen Viet Nhung, Director of National Lung Hospital, Manager of National TB Programme, Hanoi, Viet Nam; Ejaz Qadeer, Ministry of Health, Islamabad, Pakistan; Abdul Hamid Salim, Advisor to National TB Programme Bangladesh on Global Fund and MDR-TB, Mohakhali, Dhaka, Bangladesh; Simon Schaaf, Paediatrician, Paediatrics and Child Health, Faculty of Medicine and Health Sciences, University of Stellenbosch, South Africa; Holger Schünemann (Chair), Methodologist, McMaster University, Hamilton, Canada; Pedro Guillermo Suarez, Management Sciences for Health, Arlington, VA, United States of America (Unable to attend the meeting); Carrie Tudor, TB Project Director, International Council of Nurses, Durban, South Africa; Justin Wong Yun Yaw, Head, Disease Control Division, Ministry of Health, Jalan Menteri Besar, Brunei.
Evidence reviewers
Narges Alipanah, Santa Clara Valley Medical Center, San Jose, CA, United States of America
Lelia Chaisson, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States of America
Jennifer Ho, Woolcock Institute of Medical Research, University of Sydney, Australia
James Johnston, TB Services, British Columbia Centre for Disease Control, Vancouver, Canada
Dick Menzies, RECRU/Montreal Chest Institute, Montreal, Canada
Payam Nahid, Professor, University of California, San Francisco, CA, United States of America.
Observers
Amy Bloom, US Agency for International Development (USAID), Washington, DC, United States of America
Janet Ginnard, UNITAID, Geneva, Switzerland.
WHO Steering Group
Global TB Programme: Annabel Baddeley, Dennis Falzon, Giuliano Gargioni, Nebiat Gebresselassie, Haileyesus Getahun, Licé Gonzalez-Angulo, Malgorzata Grzemska, Elizabeth Harausz, Ernesto Jaramillo, Avinash Kanchar, Soleil Labelle, Christian Lienhardt, Knut Lönnroth, Fuad Mirzayev, Linh Nguyen, Marco Vitoria, Diana Weil, Karin Weyer, Matteo Zignol.
External Review Group
Mohammed Aziz, WHO Regional Office for the Eastern Mediterranean
Masoud Dara, WHO Regional Office for Europe
Riitta Dlodlo, International Union Against Tuberculosis and Lung Disease, France (technical agency/ programme implementation)
Celine Garfin, Ministry of Health, Philippines (national programme/end-user)
Mirtha del Granado, WHO Regional Office for the Americas
Daniel Kibuga, WHO Regional Office for Africa
Md Khurshid Alam Hyder, WHO Regional Office for South-East Asia
Vaira Leimane, Riga East University Hospital, Centre of Tuberculosis and Lung Diseases, Latvia (clinician/end-user)
Nobuyuki Nishikiori, WHO Regional Office for the Western Pacific
Lee Reichman Rutgers, New Jersey Medical School, Newark, NJ, United States of America (clinician/ end-user)
Rohit Sarin, National Institute of TB & Respiratory Diseases, Ministry of Health, India (national programme/end-user)
Dalene von Delft, TB Proof, South Africa (patient representative)
Fraser Wares, Royal Dutch Tuberculosis Foundation (KNCV), The Hague, Netherlands (technical agency/programme implementation).
Guidelines on management of tuberculosis in children and adolescents, 2022
Guideline Development Group (GDG) members
Susan Abdel-Rahman (Children’s Mercy Research Institute, United States of America)
Deepak Agrawal (Aarogyam Paediatrics Hospital, India)
Shakil Ahmed (Dhaka Medical College, Bangladesh)
Elie Akl (American University of Beirut and Center for Systematic Reviews of Health Policy and Systems Research, Lebanon)
Valentina Aksenova (Research Institute of Phthisiopulmonology of the First M.I. Sechenov Moscow State Medical University, Russian Federation)
Farhana Amanullah (Indus Hospital, Pakistan)
Grace Bolie (National TB Programme, Democratic Republic of the Congo)
Chishala Chabala (University Teaching Hospital, Zambia)
Gunta Dravniece (PATH, Ukraine)
Connie Erkens (KNCV Tuberculosis Foundation, Netherlands)
Betina Mendez Alcântara Gabardo (Clinical Hospital Federal University of Paraná, Brazil)
Stephen Graham (University of Melbourne, Australia)
Patrik Hummel (Friederich-Alexander University, Germany)
Amir M. Khan (Association for Social Development, Pakistan)
Margaret Nasil Kal (National TB Programme, Papua New Guinea)
Tamara Kredo (South African Cochrane Centre, South African Medical Research Council, South Africa)
Susan Maloney (Centers for Disease Control and Prevention, United States of America)
Anna Mandalakas (Baylor College of Medicine, Texas Children’s Hospital, United States of America)
Sushant Mane (Grant Government Medical College and Sir J.J. Group of Hospitals, India)
Lindsay McKenna (Treatment Action Group, United States of America)
Imran Pambudi (National TB Programme, Indonesia)
Phan Huu Phuc (National Paediatric Hospital, Viet Nam)
Moorine Sekadde (National TB and Leprosy Programme, Uganda)
Kathryn Snow (University of Melbourne, Australia)
Sabira Tahseen (National TB Reference Laboratory, Pakistan)
Elie Akl, Farhana Amanullah, Stephen Graham and Tamara Kredo co-chaired the GDG meeting.
Technical resource persons and observers
Pete Dodd (Sheffield University, United Kingdom of Great Britain and Northern Ireland), Anneke Hesseling (Stellenbosch University, South Africa), Oliver Marcy (University of Bordeaux, France), Nicole Salazar-Austin (Johns Hopkins University, United States of America) and James Seddon (Imperial College London, United Kingdom) served as technical resource persons during the GDG meeting.
The following persons participated as observers during the GDG meeting: Draurio Barreira Cravo Neto (Unitaid, Switzerland); Charlotte Colvin (USAID, United States of America); Anne Detjen (UNICEF, United States of America); Thomas Gradel (Unitaid, Switzerland); Brian Kaiser (Stop TB Partnership Global Drug Facility, Switzerland); Michael McCaul (Stellenbosch University, South Africa); Lawrence Mbuagbaw (St Joseph’s Healthcare, Canada); Celeste Naude (Stellenbosch University, South Africa); Oxana Rucsineanu (TB Community Advisory Board); Anna Scardigli (Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland); Cherise Scott (Unitaid, Switzerland).
External Review Group
Martina Casenghi (Elizabeth Glaser Pediatric AIDS Foundation, Switzerland)
Anthony Enimil (Komfo Anokye Teaching Hospital, Ghana)
Malgorzata Grzemska (former WHO staff member, Poland)
Catherine Hewison (Médecins Sans Frontières, France)
Devan Jaganath (University of California San Francisco, United States of America)
Kobto Ghislain Koura (The International Union Against Tuberculosis and Lung Disease, France)
Celia Martínez de Cuellar (Hospital de Clínicas, Universidad Nacional de Asunción, Paraguay)
Ya Diul Mukadi (United States Agency for International Development [USAID], United States of America)
Rahab Mwaniki (Kenya Aids NGOs Consortium [KANCO], Kenya)
Marc Nicol (University of Western Australia, Australia)
Elizabeth Maleche Obimbo (University of Nairobi, Kenya)
Peter Owiti (Wote Youth Development Project, Kenya)
Nyan Win Phyo (Civil Society Taskforce; World Vision, Thailand)
Ramatoulaye Sall (Independent Consultant, Senegal)
Rina Triasih (Universitas Gadyah Mada, Indonesia)
Eric Wobudeya (Mulago National Referral Hospital, Uganda; Makerere University – Johns Hopkins University [MU-JHU] Research Collaboration, Uganda).
Evidence reviewers
Yael Hirsch-Moverman (Columbia University, United States of America), Hamidah Hussain (Interactive Research and Development [IRD] Global, Singapore), Daria Szkwarko (Brown University, United States of America) and Courtney Yuen (Harvard Medical School, United States of America) conducted the evidence review for PICO Question 6: Models of care for TB case detection and TB prevention in high TB burden settings.
WHO Steering Group
Annabel Baddeley, Lice Gonzalez Angulo, Ernesto Jaramillo, Avinash Kanchar, Charalambos Sismanidis (WHO Global Tuberculosis Programme); Martina Penazzato (WHO Global HIV, Hepatitis and Sexually Transmitted Infections Programme); Bernadette Cappello, Lorenzo Moja (WHO Department of Health Products, Policy and Standards); Marie Valentin (WHO Department of Regulation and Prequalification); Corinne Simone Collette Merle (WHO Special Programme for Research and Training in Tropical Diseases); Valentina Baltag, Wilson Milton Were (WHO Department of Maternal, Newborn, Child & Adolescent Health & Ageing); Lina Mahy (WHO Department of Nutrition and Food Safety); Chiara Servili (WHO Department of Mental Health and Substance Use); Sarah Rylance (WHO Department of Noncommunicable Diseases Management); Ogtay Gozalov (WHO Regional Office for Europe); Mukta Sharma (WHO Regional Office for South East Asia); Kyung Hyun Oh (WHO Regional Office for the Western Pacific Region); Pedro Avedillo (Pan American Health Organization); Kenza Bennani, Martin van den Boom (WHO Regional Office for the Eastern Mediterranean Region); André Ndongosieme (WHO Regional Office for Africa).
Experts participating in the development of the guidelines on DR-TB treatment, 2011
Guideline Development Group (GDG) members
Jaime Bayona, Socios En Salud Sucursal, Peru (programme management, public health); José A. Caminero, University General Hospital of Gran Canaria, Spain and the UNION, Paris, France (clinical practice); Charles L. Daley, National Jewish Health, United States of America (clinical practice); Agnes Gebhard, Royal Dutch Tuberculosis Foundation (KNCV), Netherlands (programme management); Myriam Henkens, Médecins Sans Frontières, France (programme management); Timothy H. Holtz, HIV/STD Research Program, United States Centers for Disease Control and Prevention (CDC), Asia Regional Office, Thailand (epidemiology, surveillance, programme evaluation); Joël Keravec, Management Sciences for Health, Brazil (drug management); Salmaan Keshavjee, Harvard Medical School, United States of America (programme management, public health); Aamir J. Khan, Indus Hospital TB Program, Pakistan (epidemiology, programme management); Vaira Leimane, State Infectology Center, Clinic of Tuberculosis and Lung Diseases, Latvia (programme management, clinical practice); Andrey Mariandyshev, Northern State Medical University, Archangelsk, Russian Federation (clinical practice); Carole D. Mitnick, Harvard Medical School, United States of America (epidemiology, programme support); Gloria Nwagboniwe, Alliance for Hope, Nigeria (civil society); Domingo Palmero, Pulmonology Division, Hospital Muñiz, Argentina (clinical practice); Ma. Imelda Quelapio, Tropical Disease Foundation, Philippines (programme management); Michael L. Rich, Partners In Health, United States of America (clinical practice); Sarah Royce, PATH, United States of America (surveillance, public health); Sabine Rüsch-Gerdes, National Reference Centre for Mycobacteria, Germany (laboratory specialist); Archil Salakaia, Management Sciences for Health, United States of America (programme management); Rohit Sarin, LRS Institute of TB and Allied Diseases, India (clinical practice); Holger Schünemann, McMaster University, Canada (Chairman of the Guideline Development Group; epidemiology, guideline methodology); Elena Skachkova, Federal Centre of TB Monitoring, Russian Federation (surveillance); Francis Varaine, Médecins Sans Frontières, France (clinical and programme management).
WHO steering group
Global TB Programme: Léopold Blanc, Dennis Falzon, Christopher Fitzpatrick, Katherine Floyd, Haileyesus Getahun, Malgorzata Grzemska, Christian Gunneberg, Ernesto Jaramillo, Christian Lienhardt, Fuad Mirzayev, Paul Nunn, Mario C. Raviglione, Delphine Sculiera, Fraser Wares, Karin Weyer, Matteo Zignol. HIV Department: Chris Duncombe, Marco Antonio de Avila Vitoria.
External Review Group
Samiha Baghdadi, WHO Regional Office for the Eastern Mediterranean, Egypt
Mercedes Becerra, Harvard Medical School, United States of America (academia)
Vineet Bhatia, WHO Regional Office for South-East Asia, India
Masoud Dara, WHO Regional Office for Europe, Denmark
Mirtha del Granado, WHO Regional Office for the Americas, United States of America
Reuben Granich, WHO HIV Department, Switzerland
Lindiwe Mvusi, Department of Health, South Africa (programme management)
Nani Nair, WHO Regional Office for South-East Asia, India
Norbert Ndjeka, Department of Health, South Africa (programme management, clinical practice)
Wilfred A.C Nkhoma, WHO Regional Office for Africa, Zimbabwe
Katsunori Osuga, WHO Regional Office for the Western Pacific, Philippines
Hendrik Simon Schaaf, Department of Paediatrics and Child Health, Stellenbosch University and Tygerberg Children’s Hospital, South Africa (clinical practice, paediatric MDR-TB, surveillance)
Catharina van Weezenbeek, WHO Regional Office for the Western Pacific, Philippines
Irina Vasilyeva, Central TB Research Institute of RAMS, Russian Federation (research, clinical practice)
Wang Xie Xiu, Tianjin Centers for Disease Control and Prevention, China (surveillance)
Richard Zaleskis, WHO Regional Office for Europe, Denmark
Evidence review teams
Chunling Lu, Carole D. Mitnick, Harvard Medical School, Boston MA, and Richard A. White, Harvard School of Public Health, Boston MA, United States of America.
Gail Kennedy, George Rutherford, Karen Steingart, University of California (San Francisco), California, United States of America. Matthew Arentz, David Horne, Patricia Pavlinac, Judd L. Walson, University of Washington, Seattle, Washington WA, United States of America.
Melissa Bauer, Richard (Dick) Menzies, Olivia Oxlade, McGill University, Montreal, Quebec, Canada. Consultant: Patricia Whyte, Griffith University, Queensland, Australia (guideline development).